N H Thoennissen

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. ncbi Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells
    Nils H Thoennissen
    Division of Hematology and Oncology, Cedars Sinai Medical Center, University of California Los Angeles School of Medicine, Los Angeles, California 90048, USA
    Cancer Res 69:5876-84. 2009
  2. ncbi Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway
    N H Thoennissen
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Oncogene 29:285-96. 2010
  3. ncbi Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms
    Nils H Thoennissen
    Division of Hematology and Oncology, Cedars Sinai Medical Center, University of California Los Angeles School of Medicine, Los Angeles, CA 90048, USA
    Blood 115:2882-90. 2010
  4. ncbi Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer
    Gabriela B Iwanski
    Division of Hematology and Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Br J Pharmacol 160:998-1007. 2010
  5. ncbi Cucurbitacin: ancient compound shedding new light on cancer treatment
    Dhong Hyun Lee
    Division of Hematology and Oncology, Cedars Sinai Medical Center, School of Medicine, University of California, Los Angeles, CA, USA
    ScientificWorldJournal 10:413-8. 2010

Detail Information

Publications5

  1. ncbi Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells
    Nils H Thoennissen
    Division of Hematology and Oncology, Cedars Sinai Medical Center, University of California Los Angeles School of Medicine, Los Angeles, California 90048, USA
    Cancer Res 69:5876-84. 2009
    ..Further clinical studies are necessary to confirm our findings in patients with pancreatic cancer...
  2. ncbi Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway
    N H Thoennissen
    Division of Hematology Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Oncogene 29:285-96. 2010
    ..Our data indicate that capsaicin is a novel modulator of the EGFR/HER-2 pathway in both ER-positive and -negative breast cancer cells with a potential role in the treatment and prevention of human breast cancer...
  3. ncbi Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms
    Nils H Thoennissen
    Division of Hematology and Oncology, Cedars Sinai Medical Center, University of California Los Angeles School of Medicine, Los Angeles, CA 90048, USA
    Blood 115:2882-90. 2010
    ..01 and P = .016, respectively). Our high-density SNP-array analysis of MPN genomes in the chronic compared with leukemic stage identified novel target genes and provided prognostic insights associated with the evolution to leukemia...
  4. ncbi Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer
    Gabriela B Iwanski
    Division of Hematology and Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Br J Pharmacol 160:998-1007. 2010
    ..Recently, we showed that the triterpenoid cucurbitacin B inhibited tumour growth in pancreatic cancer cells by inhibition of the JAK/STAT pathway, and synergistically increased antiproliferative effects of gemcitabine in vitro...
  5. ncbi Cucurbitacin: ancient compound shedding new light on cancer treatment
    Dhong Hyun Lee
    Division of Hematology and Oncology, Cedars Sinai Medical Center, School of Medicine, University of California, Los Angeles, CA, USA
    ScientificWorldJournal 10:413-8. 2010
    ..In this review, we will summarize the recent discoveries regarding molecular mechanisms of action of cucurbitacins in human cancer cells and discuss the possibilities of cucurbitacin as a future anticancer drug in clinical settings...